Comment on "Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome"

被引：3
|
作者：
Hollenack, Kelly [1 ]
Marshall, Jade [2 ]
机构：
[1] Greenwich Biosci Inc, 5750 Fleet St,Suite 200, Carlsbad, CA 92008 USA
[2] GW Pharma Ltd, London, England
来源：
PHARMACOECONOMICS | 2021年 / 39卷 / 04期
关键词：
D O I：
10.1007/s40273-021-01005-w
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：473 / 475
页数：3
相关论文
共 50 条
  • [11] COST-EFFECTIVENESS ANALYSIS OF ANTIEPILEPTIC DRUGS IN THE TREATMENT OF LENNOX-GASTAUT SYNDROME
    Clements, K. M.
    Skornicki, M.
    O'Sullivan, A. K.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A144 - A144
  • [12] Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome
    Lattanzi, S.
    Trinka, E.
    Russo, E.
    Striano, P.
    Citraro, R.
    Silvestrini, M.
    Brigo, F.
    [J]. DRUGS OF TODAY, 2019, 55 (03) : 177 - 196
  • [13] CINROMIDE IN THE TREATMENT OF SEIZURES IN THE LENNOX-GASTAUT SYNDROME
    LOCKMAN, LA
    ROTHNER, AD
    ERENBERG, G
    WRIGHT, FW
    CLOUTIER, G
    GEIGER, EH
    [J]. EPILEPSIA, 1981, 22 (02) : 241 - 241
  • [14] The Cost Effectiveness of Rufinamide in the Treatment of Lennox-Gastaut Syndrome in the UK
    Ágnes Benedict
    Lara Verdian
    Grant Maclaine
    [J]. PharmacoEconomics, 2010, 28 : 185 - 199
  • [15] The Cost Effectiveness of Rufinamide in the Treatment of Lennox-Gastaut Syndrome in the UK
    Benedict, Agnes
    Verdian, Lara
    Maclaine, Grant
    [J]. PHARMACOECONOMICS, 2010, 28 (03) : 185 - 199
  • [16] LENNOX-GASTAUT SYNDROME - TREATMENT OF SEIZURES WITH FELBAMATE
    GAROFALO, EA
    OLSON, LD
    SACKELLARES, JC
    KOMARYNSKI, MA
    TORNOW, MA
    TRIPATHI, A
    [J]. ANNALS OF NEUROLOGY, 1991, 30 (03) : 492 - 492
  • [17] COST-UTILITY OF CANNABIDIOL IN ADDITION TO BACKGROUND THERAPY VERSUS BACKGROUND THERAPY ALONE IN LENNOX-GASTAUT SYNDROME
    Neuberger, E.
    Veenstra, D. L.
    [J]. VALUE IN HEALTH, 2019, 22 : S273 - S273
  • [18] Erratum to: The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK
    Á Benedict
    L Verdian
    G Maclaine
    [J]. PharmacoEconomics, 2011, 29 : 1014 - 1014
  • [19] Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox-Gastaut syndrome
    Faulkner, Michele A.
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 905 - 914
  • [20] Exposure-Response Analysis of Cannabidiol for the Treatment of Lennox-Gastaut Syndrome
    Morrison, G.
    Sardu, M. L.
    Rasmussen, C. H.
    Sommerville, K.
    Roberts, C.
    Blakey, G. E.
    [J]. EPILEPSIA, 2018, 59 : S11 - S12
12345